BioCentury
ARTICLE | Clinical News

AVI-7100: Phase I data

November 10, 2014 8:00 AM UTC

Data from 40 healthy volunteers in the single ascending-dose portion of a double-blind, placebo-controlled, U.S. Phase I trial showed that IV AVI-7100 was well tolerated at doses of up to 8 mg/kg. No ...